期刊
ANTIOXIDANTS
卷 11, 期 11, 页码 -出版社
MDPI
DOI: 10.3390/antiox11112224
关键词
cardiovascular disease; kidney disease; anti-inflammation; antioxidation; hydralazine
资金
- Taipei Veterans General Hospital, Taipei, Taiwan
- Ministry of Science and Technology, Taipei, Taiwan
- [VSVH-11005]
- [VSVH-11006]
- [MOST 110-2314-B-A49A-552-MY3]
Hydralazine, a traditional antihypertensive drug, not only lowers blood pressure but also shows potential in treating vascular and kidney diseases. Recent experimental studies suggest that it has antioxidative, anti-apoptotic, and HIF-1 alpha stabilization effects, promoting angiogenesis and providing vascular protection. Its reno-protective effects are achieved through antioxidation, DNA demethylation, and anti-inflammation abilities, indicating its potential for treating kidney diseases.
Hydralazine is a traditional antihypertensive drug that was developed several decades ago. Its most well-known effect is blood pressure lowering by arterial vasodilation. While mainly used an adjunct treatment for clinical hypertension or chronic heart failure, this old drug has also shown potential as a repurposing drug for the atherosclerosis vascular disease and various kidney diseases. Recent experimental studies suggest that hydralazine exerts antioxidative, anti-apoptotic, and HIF-1 alpha stabilization effects for angiogenesis and vascular protection. Hydralazine also exerts reno-protective effects via its antioxidation, DNA demethylation, and anti-inflammation abilities. The above evidence provides advanced rationales for new applications of this drug beyond blood pressure lowering and arterial vasodilation. Here, we summarized the recent experimental advances in the use of hydralazine for either a vascular disease or kidney diseases, or both. Given the wide populations of people with cardiovascular and/or kidney diseases, future studies are worth validating the potential impacts of hydralazine on the clinical outcomes in selected patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据